• Je něco špatně v tomto záznamu ?

Innate Immune Response in Hypertension

JB. De Sanctis

. 2022 ; 28 (36) : 2984-2990. [pub] -

Jazyk angličtina Země Spojené arabské emiráty

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033376

Even though an association between inflammation and hypertension has been known for many years, it has not been simple to ascertain the role of several physiological responses involved. The innate immune response plays a critical role in these physiological responses. Innate immune cells can be activated directly by shear stress, activate the inflammasome and produce numerous cytokines and soluble mediators essential in hypertension. NFkB activation is mainly involved in the activation of innate immune cells. Shear stress also stimulates the expression of DAMP and PAMP receptors, enhancing pathogen and danger signals and magnifying inflammation. The adaptative immune response is activated with the increased antigen presentation resulting from the insults mentioned. Chronic inflammation may lead to autoimmunity. Peripheral hypoxia, a consequence of hypertension, activates hypoxia-inducing factors 1-α and 1-β (HIF-1α, HIF-1β), which modulate innate immune cells and promote inflammation. HIF-1α is involved in the upregulation of oxygen and nitrogen radical production proteins. HIF-1β down-regulates antioxidant enzymes. However, the critical evidence of the role of innate immune cells in hypertension came from the results of clinical trials involving therapies blocking inflammatory cytokines and Toll-like receptor expression. Several lines of research have been conducted on this complex disease. Pro-tolerogenic innate immune cells, myeloid suppressor cells, and M2 macrophages may play a crucial role in promoting or resolving inflammation, cardiovascular diseases and hypertension, and should be studied in detail.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033376
003      
CZ-PrNML
005      
20230131151517.0
007      
ta
008      
230120s2022 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1381612828666220922112412 $2 doi
035    __
$a (PubMed)36154596
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a De Sanctis, Juan Bautista $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
245    10
$a Innate Immune Response in Hypertension / $c JB. De Sanctis
520    9_
$a Even though an association between inflammation and hypertension has been known for many years, it has not been simple to ascertain the role of several physiological responses involved. The innate immune response plays a critical role in these physiological responses. Innate immune cells can be activated directly by shear stress, activate the inflammasome and produce numerous cytokines and soluble mediators essential in hypertension. NFkB activation is mainly involved in the activation of innate immune cells. Shear stress also stimulates the expression of DAMP and PAMP receptors, enhancing pathogen and danger signals and magnifying inflammation. The adaptative immune response is activated with the increased antigen presentation resulting from the insults mentioned. Chronic inflammation may lead to autoimmunity. Peripheral hypoxia, a consequence of hypertension, activates hypoxia-inducing factors 1-α and 1-β (HIF-1α, HIF-1β), which modulate innate immune cells and promote inflammation. HIF-1α is involved in the upregulation of oxygen and nitrogen radical production proteins. HIF-1β down-regulates antioxidant enzymes. However, the critical evidence of the role of innate immune cells in hypertension came from the results of clinical trials involving therapies blocking inflammatory cytokines and Toll-like receptor expression. Several lines of research have been conducted on this complex disease. Pro-tolerogenic innate immune cells, myeloid suppressor cells, and M2 macrophages may play a crucial role in promoting or resolving inflammation, cardiovascular diseases and hypertension, and should be studied in detail.
650    _2
$a lidé $7 D006801
650    12
$a přirozená imunita $7 D007113
650    _2
$a zánět $x metabolismus $7 D007249
650    _2
$a cytokiny $x metabolismus $7 D016207
650    _2
$a hypoxie $7 D000860
650    12
$a hypertenze $7 D006973
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
773    0_
$w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 28, č. 36 (2022), s. 2984-2990
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36154596 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151513 $b ABA008
999    __
$a ok $b bmc $g 1891904 $s 1184711
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 28 $c 36 $d 2984-2990 $e - $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...